These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1649765)

  • 21. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of radioprotective agents on X-ray cataracts.
    Reddy VN; Ikebe H; Giblin FJ; Clark JI; Livesey JC
    Lens Eye Toxic Res; 1989; 6(4):573-88. PubMed ID: 2562120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral toxicity and efficacy of WR-2721 as a radioprotectant.
    Bogo V; Jacobs AJ; Weiss JF
    Radiat Res; 1985 Nov; 104(2 Pt 1):182-90. PubMed ID: 3001816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys.
    Levi M; Knol JA; Ensminger WD; DeRemer SJ; Dou C; Lunte SM; Bonner HS; Shaw LM; Smith DE
    Drug Metab Dispos; 2002 Dec; 30(12):1425-30. PubMed ID: 12433814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic approaches to protection against radiation-induced lethality and other damage.
    Weiss JF
    Environ Health Perspect; 1997 Dec; 105 Suppl 6(Suppl 6):1473-8. PubMed ID: 9467066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Competition for polyamine uptake into rat lung slices by WR2721 and analogues.
    Wyatt I; Moore RB; Smith LL
    Int J Radiat Biol; 1989 Mar; 55(3):463-72. PubMed ID: 2564041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA; Siden R
    Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The cytoprotective agent amifostine (WR-2721): current clinical use and trends in its development].
    Dragojević-Simić V; Dobrić S
    Vojnosanit Pregl; 1996; 53(4):305-10. PubMed ID: 9229947
    [No Abstract]   [Full Text] [Related]  

  • 29. An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma.
    Swynnerton NF; McGovern EP; Niño JA; Mangold DJ
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1521-4. PubMed ID: 6090354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioprotection by vitamin E: injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice.
    Srinivasan V; Weiss JF
    Int J Radiat Oncol Biol Phys; 1992; 23(4):841-5. PubMed ID: 1319980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine.
    Castiglione F; Dalla Mola A; Porcile G
    Tumori; 1999; 85(2):85-91. PubMed ID: 10363072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
    Church MW; Blakley BW; Burgio DL; Gupta AK
    J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal absorption of radioprotectors in the rat using permeation-enhancing vehicles.
    Lamperti A; Ziskin MC; Bergey E; Gorlowski J; Sodicoff M
    Radiat Res; 1990 Nov; 124(2):194-200. PubMed ID: 2174175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721).
    Thompson DC; Wyrick SD; Holbrook DJ; Chaney SG
    Biochem Pharmacol; 1995 Oct; 50(9):1413-9. PubMed ID: 7503792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration.
    Mangold DJ; Miller MA; Huelle BK; Sanchez-Barona DO; Swynnerton NF; Fleckenstein L; Ludden TM
    Drug Metab Dispos; 1989; 17(3):304-10. PubMed ID: 2568913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The disposition of ethiofos (WR-2721) in the isolated perfused rat liver.
    Coleman MD; Fleckenstein L; Geary RS; Brewer TG; Timony GA; Mangold DJ
    Radiat Res; 1989 Feb; 117(2):334-41. PubMed ID: 2537989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxy derivates of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate and related compounds as antiradiation agents.
    Piper JR; Rose LM; Johnston TP; Grenan MM
    J Med Chem; 1975 Aug; 18(8):803-12. PubMed ID: 1159697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase-separation inhibitors and prevention of selenite cataract.
    Clark JI; Steele JE
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1720-4. PubMed ID: 1311849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical modification of normal tissue damage induced by photodynamic therapy.
    Sigdestad CP; Fingar VH; Wieman TJ; Lindberg RD
    Br J Cancer Suppl; 1996 Jul; 27():S89-92. PubMed ID: 8763855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.